The obesity drug market is booming.
But the stock market is treating these two companies very differently.
Eli Lilly is now worth roughly $1.08 trillion.
Novo Nordisk sits around $199 billion.
That’s an $881 billion gap between two companies leading one of the fastest-growing drug markets in history.
The obvious question is why.
Eli Lilly has taken the lead with Zepbound and Mounjaro, while Novo Nordisk continues to rely on Wegovy and Ozempic.
Investors are rewarding Lilly for stronger sales growth, a broader drug pipeline, and expectations that it will remain the market leader.
But leadership comes at a price.
Lilly trades at roughly 41 times earnings, leaving very little room for disappointment if future trial results, competition, or demand fail to meet expectations.
Novo tells a very different story.
Its valuation has fallen enough that it now trades around 11.5 to 12.6 times earnings, despite generating strong cash flow and remaining one of the biggest players in the GLP-1 market.
That’s why the debate is becoming more interesting.
Lilly looks like the company everyone wants to own.
Novo looks like the company value investors are starting to notice.
The next battleground isn’t today’s injectable drugs.
It’s tomorrow’s products.
Both companies are racing to improve oral GLP-1 treatments, expand into new diseases, and defend their patents while more competitors enter the market.
The weight loss story isn’t slowing down.
The question is whether investors are paying too much for the current leader or too little for the company trying to catch up.
In markets, the best business isn’t always the best stock.
Sometimes the biggest opportunity comes from the gap between expectations and reality.
Disclaimer: Not financial advice